These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17912629)

  • 1. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases.
    Turbin DA; Leung S; Cheang MC; Kennecke HA; Montgomery KD; McKinney S; Treaba DO; Boyd N; Goldstein LC; Badve S; Gown AM; van de Rijn M; Nielsen TO; Gilks CB; Huntsman DG
    Breast Cancer Res Treat; 2008 Aug; 110(3):417-26. PubMed ID: 17912629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of hormone receptor status in breast cancer.
    Horii R; Akiyama F; Ito Y; Iwase T
    Pathol Int; 2007 Dec; 57(12):784-90. PubMed ID: 17988279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
    Iwase H; Zhang Z; Omoto Y; Sugiura H; Yamashita H; Toyama T; Iwata H; Kobayashi S
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S34-8. PubMed ID: 12819932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor beta expression in invasive breast cancer.
    Mann S; Laucirica R; Carlson N; Younes PS; Ali N; Younes A; Li Y; Younes M
    Hum Pathol; 2001 Jan; 32(1):113-8. PubMed ID: 11172304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.
    Biesterfeld S; Veuskens U; Schmitz FJ; Amo-Takyi B; Böcking A
    Anticancer Res; 1996; 16(5A):2497-500. PubMed ID: 8917341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer.
    McClelland RA; Finlay P; Walker KJ; Nicholson D; Robertson JF; Blamey RW; Nicholson RI
    Cancer Res; 1990 Jun; 50(12):3545-50. PubMed ID: 2187598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
    Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
    Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of GATA3 expression in breast cancer: a 10-year follow-up study.
    Ciocca V; Daskalakis C; Ciocca RM; Ruiz-Orrico A; Palazzo JP
    Hum Pathol; 2009 Apr; 40(4):489-95. PubMed ID: 19084267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer.
    de Souza Sales JF; Cabello C; Alvarenga M; Torresan RZ; Duarte GM
    Breast; 2007 Apr; 16(2):197-203. PubMed ID: 17178225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.
    Owusu C; Buist DS; Field TS; Lash TL; Thwin SS; Geiger AM; Quinn VP; Frost F; Prout M; Yood MU; Wei F; Silliman RA
    J Clin Oncol; 2008 Feb; 26(4):549-55. PubMed ID: 18071188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories.
    Regitnig P; Reiner A; Dinges HP; Höfler G; Müller-Holzner E; Lax SF; Obrist P; Rudas M; Quehenberger F
    Virchows Arch; 2002 Oct; 441(4):328-34. PubMed ID: 12404057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.